SDBJ Insider: Halozyme’s Platform Keeps Delivering For Company

The partnership deals just keep rolling in for Halozyme Therapeutics’ drug delivery technology.

Gossamer Bio Goes Public with Upsized $276M Offering

Gossamer Bio — a closely watched San Diego biotech during the government shutdown — made its public debut Feb. 8 with an upsized $276 million offering.

As Deadline Looms, Biotechs Take Stock of Last Government Shutdown

The government shutdown ended Jan. 25, but lingering effects are evident in San Diego life sciences, from a halted merger to initial public offerings.

Tease photo

Equillium Receives Orphan Drug Designations

The U.S. Food and Drug Administration granted orphan drug designations to San Diego-based Equillium’s drug candidate for the prevention and treatment of a tissue disease.

Biotech Investors Often Bet on Familiar Faces

FINANCE: Investors See Pluses In Past Success, Experience

San Diego biotech’s growing roster of rising stars and veteran leaders helped propel the region to new fundraising heights in 2018, observers say.

Neurocrine Reports Fourth Quarter Results

San Diego biotech Neurocrine’s fourth quarter earnings largely beat analyst expectations.

From Little Known to IPO: INmune Bio Raises $8.16 Million in Trading Debut

In the first biotech initial public offering of the year, La Jolla-based INmune Bio took in $8.16 million during its trading debut. The Nasdaq listing also raised the profile of what’s been a quiet operation.

Halozyme Nets $30 Million Upfront in Argenx Licensing Deal

Halozyme has licensed its drug delivery technology to yet another company.

Nanomedical Diagnostics Changes Company Name

San Diego-based Nanomedical Diagnostics is now known as Cardea.

Gossamer Bio Is Back on Track For a Traditional IPO

With the government shutdown over, Gossamer Bio will take a traditional path to an initial public offering, abandoning a plan to sidestep the U.S. Securities and Exchange Commission.

Tease photo

PE Firm Buys Stake In S.D.-Based BioDuro

Private equity firm Advent International bought a majority stake in San Diego-headquartered BioDuro for an undisclosed amount, according to a recent announcement.

Tease photo

Relatively Cheap Rent in County a Sweetner for Biotechs

San Diego lab rents in the prior four years were consistently lower than the country’s two larger life sciences markets, San Francisco and Boston.

Tease photo

Gossamer Bio Back to a Traditional IPO Path

With the government shutdown over, Gossamer Bio is expected to take a traditional path to an initial public offering, abandoning a plan to sidestep the U.S. Securities and Exchange Commission.

Tease photo

Neurocrine Bags Gene Therapies for $165 Million Upfront

San Diego-based Neurocrine will pay Voyager Therapeutics $165 million upfront as part of a larger pact, it was announced Jan. 29.

Illumina Reports Q4 Results

Illumina reported an 11 percent increase in fourth quarter revenue after the market closed Jan. 29.